Navigation Links
Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Date:8/19/2010

LONDON, Aug. 19 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc. ("Quark"), has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.

Quark is currently conducting a Phase II clinical trial of QPI-1002 for the prevention of acute kidney injury in patients undergoing cardiac surgery and for delayed graft function in kidney transplant patients.  Based on the announcement issued by Quark on 18 August 2010, and under the terms of Silence's agreement with Quark, Silence anticipates that its future milestone payments from this program could potentially exceed $65 million.    

Commenting on today's announcement, Phil Haworth, CEO of Silence, said: "We are delighted that Novartis has chosen to take this development option for QPI-1002.  This serves as further validation of Silence's leading AtuRNAi technology and we look forward to receiving the significant milestones as the development of QPI-1002 continues."

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ uses a libra
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
10. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
11. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... Investors to Attend Conference, MONTREAL, Sept. 12 ... announced that Mr. Pierre Laurin, President,and Chief Executive ... Investor Summit on September 16, 2008 at 16:00 ... Hopkins InterContinental Hotel in San Francisco., More ...
... Exosome Diagnostics, Inc. today,announced the appointment of ... this role, Dr. Skog will oversee the research ... diagnostics that can,identify cancer-specific genetic mutations., Dr. ... Exosome Diagnostics,core technology that has been licensed exclusively ...
... Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: CPRX ), ... prescription drugs,for the treatment of drug addiction and ... into definitive agreements with,institutional investors to sell 1,488,332 ... $3.00 per share in a registered direct common ...
Cached Biology Technology:ProMetic to present at Merriman Curhan Ford's Investor Summit 2008 on September 16th 2Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering 2Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering 3
(Date:7/11/2014)... Standards and Technology (NIST) need a special tool ... prove that necessity is truly the mother of ... Lorna De Leoz and Stephen Stein, NIST chemists ... is the study of the abundant, often-branched sugar ... and lipids and influence cellular processes, including immunity, ...
(Date:7/11/2014)... international team of researchers, including scientists from the Max ... a reported a major step in understanding photosynthesis, the ... maintains the oxygen in its atmosphere and which is ... earth. , The researchers report the first direct ... namely the step in which a specific protein complex, ...
(Date:7/11/2014)... mesenchymal stem cells can stimulate neurogenesis in the brain ... (AD) and improve tissue and function injury under the ... the therapeutic effect of adipose-derived stem cells (ADSCs) transplantation ... oxidative injury and neurogenesis in the brain of AD ... Life Sciences, Tsinghua University, China transplanted ADSCs into the ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... This release is available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2009-05/bc-pmp051909.php,">Chinese . ... in plants is able to take on a similar ... in the open access journal BMC Microbiology . ... in E. coli cells, polar regions keeping ...
... has been thrown on how humans choose their partners, ... European Society of Human Genetics today (Monday May 25). ... Immunogenetics and Histocompatibility Laboratory at the University of Parana, ... with diverse major histocompatibility complexes (MHCs) were more likely ...
... Molecular Medicine (MDC) Berlin-Buch, Germany, have gained crucial insight ... the sensory neurons of mice, the neurobiologists and pain ... were able to directly elucidate, for the first time, ... were able to show that neurons develop their sensitivity ...
Cached Biology News:Plant Min protein sits tight and rescues E. coli 2Opposites attract -- how genetics influences humans to choose their mates 2Investigating the development of mechanosensitivity 2
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
...
Request Info...
Biology Products: